Company news

Gilead Sciences, Inc. news in 2024

Gilead Sciences, Inc.'s news releases, calls and decks from 2024, newest first.

View company

Gilead Sciences Announces First Quarter 2024 Financial Results

April 24, 2024

Gilead Sciences to Release First Quarter 2024 Financial Results on Thursday, April 25, 2024

April 7, 2024

Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program

March 27, 2024

FDA Expands Indication for Gilead's Vemlidy (Tenofovir Alafenamide) to Treat Chronic HBV Infection in Pediatric Patients as Young as Six

March 27, 2024

Gilead Sciences Announces Completion of Acquisition of CymaBay

March 21, 2024

Gilead Sciences Announces Expiration of Hart-Scott-Rodino Waiting Period for CymaBay Tender Offer

March 10, 2024

Gilead and Merus Announce Collaboration to Discover Novel Antibody-Based Trispecific T-Cell Engagers

March 5, 2024

Gilead and Merck Announce Phase 2 Data Showing an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression at Week 24

March 5, 2024

New Real-World Data Further Support the Use of Veklury® (Remdesivir) for People Hospitalized With COVID-19

March 4, 2024

Gilead’s Innovative HIV Treatment Research Pipeline Aims to Address Unmet Needs and Advance Public Health

March 4, 2024

Gilead Announces Funding Initiative to Support HIV Prevention, Anti-Stigma and Health Equity Efforts for Black Cisgender and Transgender Women and Girls in the U.S.

February 26, 2024

U.S. FDA Approves Expanded Indication for Gilead’s Biktarvy® to Treat People with HIV with Suppressed Viral Loads, Pre-existing Resistance

February 25, 2024

Gilead to Present Late-Breaking Data and Real-World Evidence Highlighting Innovative Antiviral Portfolio and Research Pipeline at CROI 2024

February 25, 2024

Gilead Sciences Expands Liver Portfolio With Acquisition of CymaBay Therapeutics

February 11, 2024

Gilead Named One of America’s Most JUST Companies by JUST Capital and CNBC

February 8, 2024

Gilead Sciences Announces Fourth Quarter and Full Year 2023 Financial Results

February 5, 2024

Gilead Sciences Announces 2.7 Percent Increase in First Quarter 2024 Dividend

February 5, 2024

Ted Love, MD, Joins Gilead Sciences’ Board of Directors

January 31, 2024

Kite Receives U.S. FDA Approval of Manufacturing Process Change Resulting in Reduced Median Turnaround Time for Yescarta® CAR T-cell Therapy

January 29, 2024

Gilead and Arcus Announce Amended Collaboration and Equity Investment

January 28, 2024

Gilead Sciences to Release Fourth Quarter & Full Year 2023 Financial Results on Tuesday, February 6, 2024

January 22, 2024

Gilead Provides Update on Phase 3 EVOKE-01 Study

January 21, 2024

← Newer news releases

Calls in 2024

Decks in 2024